Jiajian Xiefei Tang alleviates asthma airway inflammation by regulating the STAT3/IL-17 signaling pathway through its effective component licochalcone A
- 1Respiratory Infection Department, Xinchang Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, Shaoxing 312500 China
- 2Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou 310016 China
Abstract
Jiajian Xiefei Tang (JJXFT) is a practical prescription rooted in traditional Chinese medicine clinical experiences for various pulmonary diseases. Nevertheless, its function and mechanism in asthma treatment remain unclear. An ovalbumin-induced murine asthma model was established. The effect of JJXFT on airway inflammation was assessed via histopathological examination and ELISA. Network pharmacology analysis was conducted to predict potential targets and upstream active compounds of JJXFT, followed by validation of binding interactions via molecular docking and cellular thermal shift assay. Western blot and immunofluorescence were applied to detect proteins linked to the STAT3 signaling axis. An in vitro alveolar epithelial cell injury model was built to further explore the molecular mechanism of JJXFT in ameliorating asthma. JJXFT alleviated disease progression in asthmatic mice by improving pathological conditions and airway inflammation in lung tissues. Network pharmacology analysis detected STAT3 as a potential target of JJXFT, and licochalcone A (Lico-A) as an active component. Experimental validation confirmed that Lico-A bound to STAT3, markedly suppressing its phosphorylation and nuclear translocation. In vitro studies demonstrated that Lico-A effectively reduced asthma-related cellular damage by inhibiting the STAT3/IL-17 signaling pathway. JJXFT attenuates asthma symptoms by modulating the STAT3/IL-17 signaling axis through its active component Lico-A, suggesting that JJXFT may function as a potential therapeutic agent for asthma.
Related
- Re-Du-Ning Alleviates Airway-Intestinal Inflammation of COPD Rats by Regulating Glycerophospholipid Metabolism and Modulating Gut Microbiome
- Dihydroartemisinin alleviates allergic airway inflammation by suppressing the PI3K-AKT signaling axis: integrated network pharmacology and experimental validation.
- Magnolol alleviates high-fat diet-induced steatosis, inflammation and fibrosis in obesity-associated liver injuries via MOGAT1-mediated lipid metabolism and NF-κB signaling
- Licochalcone A Attenuates Oxidative Stress and Inflammation to Promote Second-Degree Burn Healing Through Nrf2/HO-1 Activation in Mice
- Crocin alleviates renal fibrosis through inhibiting mitochondrial dysfunction via regulating HOXD8/PGC‑1α pathways
BibTeX
@article{lv2026jiajian,
title = {{Jiajian Xiefei Tang alleviates asthma airway inflammation by regulating the STAT3/IL-17 signaling pathway through its effective component licochalcone A}},
author = {Yuanjie Lv and Shengjie Wu and Xiaoping Liu},
journal = {The Korean Journal of Physiology \& Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology},
year = {2026},
month = nov,
doi = {10.4196/kjpp.25.384},
url = {https://doi.org/10.4196/kjpp.25.384},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Jiajian Xiefei Tang alleviates asthma airway inflammation by regulating the STAT3/IL-17 signaling pathway through its effective component licochalcone A
AU - Yuanjie Lv
AU - Shengjie Wu
AU - Xiaoping Liu
PY - 2026
DA - 2026/11/01
JO - The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology
DO - 10.4196/kjpp.25.384
UR - https://doi.org/10.4196/kjpp.25.384
AB - Jiajian Xiefei Tang (JJXFT) is a practical prescription rooted in traditional Chinese medicine clinical experiences for various pulmonary diseases. Nevertheless, its function and mechanism in asthma treatment remain unclear. An ovalbumin-induced murine asthma model was established. The effect of JJXFT on airway inflammation was assessed via histopathological examination and ELISA. Network pharmacology analysis was conducted to predict potential targets and upstream active compounds of JJXFT, followed by validation of binding interactions via molecular docking and cellular thermal shift assay. Western blot and immunofluorescence were applied to detect proteins linked to the STAT3 signaling axis. An in vitro alveolar epithelial cell injury model was built to further explore the molecular mechanism of JJXFT in ameliorating asthma. JJXFT alleviated disease progression in asthmatic mice by improving pathological conditions and airway inflammation in lung tissues. Network pharmacology analysis detected STAT3 as a potential target of JJXFT, and licochalcone A (Lico-A) as an active component. Experimental validation confirmed that Lico-A bound to STAT3, markedly suppressing its phosphorylation and nuclear translocation. In vitro studies demonstrated that Lico-A effectively reduced asthma-related cellular damage by inhibiting the STAT3/IL-17 signaling pathway. JJXFT attenuates asthma symptoms by modulating the STAT3/IL-17 signaling axis through its active component Lico-A, suggesting that JJXFT may function as a potential therapeutic agent for asthma.
SN - 1226-4512
SN - 2093-3827
ER -